Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Relx interim revenue, adjusted operating profits grow

(Sharecast News) - Information and analytics company Relx said on Thursday that both revenue and adjusted operating profits had grown in the six months ended 30 June, leading it to reaffirm FY guidance. Relx said revenues were up 7% at £4.74bn, while adjusted operating profits grew 9% to £1.65bn, and adjusted earnings per share of 63.5p were 10% higher at constant currency. Reported operating profits rose from £1.43bn to £1.49bn and reported earnings per share of 52.9p were modestly above the 52.6p reported in Q124.

The FTSE 250-listed group also declared an interim dividend of 19.5p, up 7% year-on-year.

Looking ahead, Relx said it continues to see "positive momentum across the group", and said it now expects to deliver "another year of strong underlying growth in revenue and adjusted operating profit", as well as strong growth in adjusted earnings per share on a constant currency basis.

Chief executive Erik Engstrom said: "Relx delivered strong revenue and profit growth in the first half of 2025, in line with full year 2024 but with a higher quality growth profile.

"Our improving long-term growth trajectory continues to be driven across the group by the ongoing shift in business mix towards higher growth analytics and decision tools that deliver enhanced value to our customers."

As of 0900 BST, Relx shares were down 0.18% at 3,888.00p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.